Below you can find more information about our Advisors
Mr. Sunil Joshi has over 25 years of experience in the biopharmaceutical industry and has strong expertise in oncology drug development and commercialization. He served as the Chief Executive Officer and President of Gradalis, Inc., served as Vice President and Global Product Team Lead for Halozyme Therapeutics, Inc. and served as Head of New Product Strategy and Commercial Assessment at Onyx Pharmaceuticals. Prior to joining Onyx, Mr. Joshi held roles of increasing responsibility in global marketing, U.S. brand marketing and sales at Bristol Myers Squibb and was responsible for product launches and commercialization of oncology products including Erbitux(R) , Ixempra(R) , and Yervoy(R) across multiple solid tumors (colorectal cancer, head and neck cancer, melanoma and breast cancer) and Sprycel(R) in chronic myelogenous leukemia, and Philadelphia positive, acute lymphoblastic leukemia. He holds an MBA from the University of Akron and a Master's Degree in Science from the University of Mumbai.
Dr. Steve Popielarski is a passionate, results-oriented leader who successfully grew businesses at high-growth startups, internal corporate ventures and Fortune 50 companies. He served at the Associate Director of Marketing at LifeScan, a J&J Company, where he was responsible for global marketing and portfolio management of OneTouch® blood glucose test strips and meters ($2Bn revenue), served as Commercial Launch Director at Ethicon Endo-Surgery, a J&J Company, and served as Product Manager at GeneOhm Sciences. He has successes across the business and product lifecycle in numerous industries and markets. Steve holds a Bachelor of Science from Rensselaer Polytechnic Institute, and a Master of Science and a PhD from California Institute of Technology.
Prior to joining VLP Therapeutics as Director of Clinical and Regulatory Affairs, Dr. George Moonsammy spent over 20 years at GlaxoSmithKline (GSK) as a biological research scientist in R&D and subsequently in clinical affairs in the anti-infective and vaccine division. He participated in the US development and launch of several vaccines including ENGERIX-B (hepatitis-B), HAVRIX (hepatitis-A) and LYMERIX (Lyme’s disease). The launch of these vaccines was the initiation of the GSK vaccine business in the US. He was the head of R&D at Somerset Pharmaceuticals, Tampa, FL., and later became the Director of Clinical and Regulatory Affairs at Fraunhofer, Center for Molecular Biotechnology where he participated in the clinical and regulatory development of plant-derived H1N1 and H5N1 influenza vaccines and a transmission blocking VLP malaria vaccine and an anthrax vaccine. Overall, he has participated in the reviewing and writing of several INDs (4), NDAs and BLAs (12) to both FDA and MHRA (UK). Dr. Moonsammy received graduate degrees at Washington University School of Medicine and The Union University and attended the Wharton Business School, University of Pennsylvania Graduate Management Program.
Dr. Angela Lynch is a toxicologist/pharmacologist with over 10 years of experience as a consultant in the chemical and pharmaceutical industry. She has experience in the strategic development and execution of nonclinical pharmacology and toxicology IND-enabling programs for small molecules and biologics to include vaccines. Dr. Lynch has expertise in study placement with CROs, study design, monitoring and interpretation of data. She is also experienced in the preparation of regulatory submissions and documents for FDA. She received her M.S.P.H. in toxicology from Tulane University in New Orleans and her Ph.D. in pharmacology from Rush University in Chicago. Dr. Lynch is an active member of the Society of Toxicology, American College of Toxicology, and the Regulatory Affairs Professional Society (RAPS). She is a published author in the fields of toxicology and pharmacology as well as has given numerous presentations at scientific conferences.
Dr. Tamaro Hudson is currently an Assistant Professor at Howard University in Department of Pharmacology and holds an appointment as a Health Research Specialist at the Washington VA Medical Center. Dr. Hudson has integrated his research focus by identifying novel signature biomarkers that could have a significant impact on both the diagnosis and targeted treatment of prostate cancer with the evaluation of new chemopreventive strategies which have been evaluated in Phase I and Phase II clinical trials. Prior to joining Howard University, Dr. Hudson completed the prestigious Cancer Prevention Fellowship Program at the National Institute of Health, National Cancer Institute, where he focused on utilizing in vitro and in vivo cancer models to assess the biological activity of bioactive compounds on prostate cancer molecular pathways. Dr. Hudson received his Bachelor of Science from Iowa State University in Biology, a Master of Science in Preventive Medicine from Ohio State University, a PhD from Ohio State University and a Master of Public Health from George Washington University.